Pyxis Oncology

Q2 FY2026 EarningsQ2 FY26 results for the period ended June 30, 2026, missed consensus across most bottom-line metrics, with revenue at $0 vs. $0.02M expected as milestone income did not materialize this quarter. Net loss of $25.3M was wider than the $23.8M consensus, driven primarily by a significant $4.5M YoY increase in G&A expenses due to severance and stock-based compensation. While R&D expenses decreased 6% YoY to $16.1M, the lack of operational cash flow resulted in a $44.2M burn for the first half of the year, raising substantial doubt about the company's ability to continue as a going concern without the recently closed $50M private placement.